Background The late cardiotoxic effects of anthracycline chemotherapy influence morbidity
and mortality in the growing population of childhood cancer survivors. Even with lower …

Background—More than 50% of> 270 000 childhood cancer survivors in the United States
have been treated with anthracyclines and are therefore at risk of developing cardiotoxicity …

Objectives: This study sought to examine the left ventricular (LV) and right ventricular (RV)
function and signs of focal fibrosis among long-term survivors of childhood cancer with the …

Purpose Quantification of left and right ventricular function using MRI in young cancer
patients treated with cardiotoxic anthracyclines. Materials and methods Twenty-eight …

Aims This study aims to assess subclinical changes in functional and morphological
myocardial magnetic resonance parameters very early into an anthracycline treatment …

Objectives: The goal of this study was to demonstrate that cardiac magnetic resonance could
reveal anthracycline-induced early tissue remodeling and its relation to cardiac dysfunction …

Background: Anthracycline-induced cardiotoxicity is a major cause of morbidity and mortality
in childhood cancer survivors (CCSs). Echocardiographic myocardial strain imaging is …

Background: Survivors of childhood cancer are at risk for anthracycline-and/or radiotherapy-
induced cardiotoxicity. Aims: The aim of this study was to assess clinical, laboratory, and …

Background Subclinical cardiotoxicity occurs in childhood cancer survivors following
moderate and high anthracycline doses. However, less is known about the subclinical …

Background Although anthracycline cardiotoxicity is clearly related to the cumulative dose
administered, subclinical cardiac dysfunction has been reported across a wide range of …